ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Dun & Bradstreet Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action

Rosen Law Firm reminded eligible Dun & Bradstreet investors of the November 10, 2026 deadline to seek lead-plaintiff status in litigation related to the company’s August 26, 2025 merger with Clearlake Capital affiliates. The merger paid D&B shareholders $9.15 per share in cash; the notice applies to certain investors who sold shares between May 13 and August 26, 2025, exchanged shares in the transaction, or held voting-eligible shares as of May 9, 2025.

Analysis

This is a post-close appraisal/fiduciary-duty overhang rather than an operating fundamental catalyst: DNB equity has already been converted to cash, so there is no direct public-equity position to express. The relevant read-through is to Clearlake’s future deal pipeline and to sponsors pursuing take-privates with thin shareholder-support margins; litigation can raise expected transaction costs, extend indemnity/escrow negotiations, and make boards demand more robust process protections.

The near-term probability of a material economic outcome is low absent discovery producing evidence of a flawed sale process, undisclosed conflicts, or a credible higher-value indication. Plaintiff-firm deadline notices are largely solicitation events and should not be treated as evidence that a claim has merit. Over 6-18 months, any adverse ruling or settlement would be more consequential for repeat sponsor counterparties by increasing perceived execution risk and potentially widening merger-arbitrage discounts on their announced transactions.

No standalone trade is warranted. The actionable implication is surveillance: identify any future Clearlake-sponsored public-company acquisition and compare its closing spread with comparable cash deals; an abnormal 150-250bp spread premium after standard financing and regulatory adjustments would indicate litigation/process risk is becoming priced. The thesis is falsified if court filings show routine disclosure-only allegations with no credible damages theory, or if subsequent Clearlake transactions close on normal timelines and spreads.

Key Decisions for Investors

• No position in DNB: the security is no longer publicly traded following cash conversion, and this notice does not create an investable operating catalyst.
• Place an event-driven alert on future announced Clearlake public-company takeovers over the next 12 months; consider long target/short sector hedge only if the annualized closing spread exceeds comparable cash-deal spreads by more than 200bp and filings show a non-routine process challenge.
• For merger-arbitrage books, avoid assigning incremental probability to a deal break solely from this deadline notice; require evidence from complaints, discovery rulings, financing changes, or a revised deal timetable before reducing close probabilities.
• Monitor the November 10, 2026 filing deadline and subsequent complaint for allegations involving valuation conflicts, management rollover, or disclosure omissions. A well-pleaded claim with documentary support would justify modestly increasing litigation-risk haircuts on future sponsor-led transactions; a boilerplate filing would not.